Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Mesothelioma 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 267Oxaliplatin 266Capecitabine 225Leucovorin 209Irinotecan 151Radiotherapy 132Bevacizumab 112Cetuximab 81Folfox protocol 49Surgical Procedures, Operative 44Radiation 41Drug Therapy 41Neoadjuvant Therapy 40Chemoradiotherapy 33Chemotherapy, Adjuvant 32Panitumumab 27XELOX 25Magnetic Resonance Spectroscopy 22Radiotherapy, Intensity-Modulated 21Floxuridine 17Biopsy 16Nivolumab 15Gemcitabine 15Early Intervention, Educational 15pembrolizumab 14Laparoscopy 14IFL protocol 14Celecoxib 14trifluridine tipiracil drug combination 13Gene Expression Profiling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rectal Neoplasms × MAC321 × Clear all
NCT00063427 2009-08-21

Study Evaluating MAC-321 in Colorectal Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
45 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡